ŠPINAROVÁ, Lenka, Jindřich ŠPINAR and Jiří VÍTOVEC. Studie MARINER (MARINER Study). Remedia. Remedia s.r.o., 2019, vol. 29, No 2, p. 147-148. ISSN 0862-8947.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Studie MARINER
Name (in English) MARINER Study
Authors ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution) and Jiří VÍTOVEC (203 Czech Republic, belonging to the institution).
Edition Remedia, Remedia s.r.o. 2019, 0862-8947.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00113405
Organization unit Faculty of Medicine
Keywords in English risk; thrombosis; embolism; rivaroxaban; clinical study
Tags rivok
Tags Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 25/9/2020 09:16.
Abstract
Studie MARINER měla za cíl zjistit, zda podávání rivaroxabanu po dobu několika týdnů sníží riziko hluboké žilní trombózy nebo nefatální či fatální plicní embolie. Při podávání rivaroxabanu nedošlo ke snížení tohoto ukazatele. Byl naznačen trend ku prospěchu u nemocných bez renální insuficience. Výskyt krvácení v celé studii byl velmi nízký.
Abstract (in English)
The MARINER study was designed to optimise the benefit/risk profile of several week administration of rivaroxaban for prevention of deep venous thrombosis , non fatal or fatal pulmonary embolism. Rivaroxaban did not influence the primary endpoint. There was a beneficial trend in patients without renal insuficiency. The risk of bleeding was low in the whole study.
Links
MSM 141100004, plan (intention)Name: Časná diagnostika kardiovaskulárních chorob
PrintDisplayed: 7/10/2024 04:18